My goodness. $XBI.

Notable and unusual options activity for $VKTX in recent weeks. Q.2 earnings release July 23. Sig surge in call volume, particularly for OTM strikes. Should be an interesting week ahead.

RT @davidycli: The unfortunate market reality for "Tech Bio" . selling into pharma as a tech solution is dangerous work. The market is (usu….

$SANA short percent of float up to 76.58% (6/13). VIVID and GLEAM data prior to year end. This may have a mighty squeeze.

What a week. Time for a good glass of wine. Enjoy your weekend!.

Investor funds purchased this, not @jaltucher. He has consultant warrants. As he vests, he banks on their backs. That's the gig. Predicting the grift is highly successful. $TAOX.

$VRTX + $SANA =.

P vs NP question unresolved. One of the seven Millennium Prize Problems, with a $1 million reward for a correct solution.

$AMD.

Insightful read. Thanks Amit for sharing. ". there’s no need for a provider or health system to care much about consumer experience since consumers aren’t the ultimate buyers, insurance companies are. Insurance companies tell consumers where they can get care and how much.

High probability, within the next year, we witness the first direct-to-consumer company acquisition of a projected pharmaceutical blockbuster/company. Innovative therapies, particularly those targeting the obesity/lifestyle/personalized medicine markets will radically reshape.

👀.

A ferocious advance in Chinese biotech is challenging Western dominance in drug innovation $XBI . => “The scale itself is not something we’ve seen before,” said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China.

$ET has a decent probability of beating estimates August 6. Will speculate $0.35-0.36 vs 0.32 consensus. Longterm hold in the office portfolio. Tax advantaged.

Debt crisis.